TEVIMBRA
GrowthmAbBLAINTRAVENOUSINJECTABLE
Approved
Dec 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
TEVIMBRA is pd-1 ligands pd-l1 and pd-l2, to the pd-1 receptor found on t cells, inhibits t-cell proliferation and cytokine production. Approved for metastatic esophageal squamous cell carcinoma (escc) after prior systemic chemotherapy. First approved in 2024.
Drug data last refreshed 15h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEVIMBRA is a monoclonal antibody (mAb) approved via BLA on December 26, 2024, administered intravenously as an injectable formulation. The specific indication and mechanism of action are not yet publicly disclosed in available data. The drug targets a defined patient population requiring IV administration.
Growth
Early-stage growth trajectory with moderate competitive pressure (30/100) creates expansion opportunities for commercial teams building market presence.
Mechanism of Action
PD-1 ligands PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.